Q4 FY2025 · ended Dec 31, 2025 · Revenue $284,000, -28.3% YoY · Filed Mar 9, 2026
Dianthus Therapeutics, Inc. (DNTH) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $1.2 billion in cash and investments and $1.2 million in total debt.
Revenue
$284,000
-28.3% vs prior quarter
Net income
$-46.64M
-26.9% vs year-ago quarter
Operating cash flow
$-50.33M
-64.7% vs year-ago quarter
Free cash flow
—
EPS
$-0.81
+16.5% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
56.31M
+31.3% vs year-ago quarter
Net cash
$1.24B
Q3 FY2026
Operating margin
-24486.3%
Q4 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1690585
- Former names
- Magenta Therapeutics, Inc. (until Sep 8, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $284,000 | $396,000 |
| Operating income | -$58.5M | -$61.5M | -$46.5M | -$69.5M | -$40.3M |
| Net income | -$46.6M | -$50.2M | -$40.8M | -$64.4M | -$36.8M |
| Diluted EPS | -$0.81 | -$0.90 | -$0.85 | -$1.43 | -$0.97 |
| Operating cash flow | -$50.3M | -$49.0M | -$28.9M | -$47.0M | -$30.6M |
| Total assets | $1.3B | $1.2B | $1.2B | $530.9M | $577.4M |
| Total liabilities | $34.8M | $41.2M | $45.6M | $37.5M | $31.0M |
| Stockholders' equity | $1.2B | $1.2B | $1.2B | $493.4M | $546.5M |
| Cash and investments | $1.2B | $1.2B | $1.2B | $514.4M | $555.5M |
| Total debt | $1.2M | $1.3M | $1.4M | $1.4M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Other events
|
Jun 12, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2026 | May 21, 2026 |
All 658 Dianthus Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.